Inhibrx Biosciences, Inc. SEC filings INBX

Inhibrx Biosciences, Inc. has 158 filings in SEC EDGAR's recent list, going back to Jan 29, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Inhibrx Biosciences, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Jun 4, 2025 —
EFFECT Filing Apr 18, 2025 —
POS EX Filing Mar 17, 2025 —
EFFECT Filing Jun 18, 2024 —
CORRESP Letter to the SEC Jun 14, 2024 —
UPLOAD Letter from the SEC Jun 14, 2024 —
SEC STAFF ACTION Filing May 24, 2024 —
CERT Filing May 24, 2024 —
CORRESP Letter to the SEC May 22, 2024 —
10-12B/A Filing May 15, 2024 —
10-12B/A Filing May 8, 2024 —
CORRESP Letter to the SEC Apr 25, 2024 —
10-12B Filing Apr 25, 2024 —
UPLOAD Letter from the SEC Apr 4, 2024 —
DRSLTR Filing Mar 4, 2024 —
DRS/A Filing Mar 4, 2024 —
UPLOAD Letter from the SEC Feb 29, 2024 —
DRS Filing Jan 29, 2024 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
INBX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
La Jolla, CA
SEC filer status
, Emerging growth company
SEC CIK
2007919

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.